Skip to content

Trial Summary

Phase I/ II first in human study of BMS-986249 (CTLA Probody) alone and in combination with nivolumab in advanced solid tumours.

Acronym:

CA030-001

ACTRN/NCT /ethics:

NCT03369223

Scientific title:

An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

Sponsor / Cooperative group:

BMS

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I; Phase II
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2017-12-05
Anticipated End Date-

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting